Log In
Print this Print this

IVAC mutanome

  Manage Alerts
Collapse Summary General Information
Company BioNTech AG
DescriptionPoly-neo-epitopic coding RNA vaccine targeting the unique mutation signature of an individual patient
Molecular Target
Mechanism of ActionVaccine; Immunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationMelanoma
Indication DetailsTreat advanced melanoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today